TET2 and acute myeloid leukemia: Moreover, integration of TET2 and FLT3‐ITD could better discriminate patients with NPM1mut AML into three prognostic subsets, with NPM1mut/FLT3‐ITD(−)/TET2(+) comparable to NPM1mut/FLT3‐ITD(+) group regarding all outcome endpoints.